PNC Financial Services Group’s Seres Therapeutics MCRB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-32
Closed -$529 4964
2024
Q4
$529 Hold
32
﹤0.01% 4520
2024
Q3
$602 Hold
32
﹤0.01% 4539
2024
Q2
$460 Hold
32
﹤0.01% 4546
2024
Q1
$502 Buy
32
+15
+88% +$323 ﹤0.01% 4497
2023
Q4
$487 Sell
17
-73
-81% -$1.92K ﹤0.01% 4417
2023
Q3
$4.28K Buy
+90
New +$6.87K ﹤0.01% 4028
2021
Q3
Hold
0
4366
2021
Q2
Hold
0
4245
2021
Q1
Hold
0
4171
2020
Q1
Sell
-2
Closed 3988
2019
Q4
$0 Hold
2
﹤0.01% 4056
2019
Q3
$0 Hold
2
﹤0.01% 4066
2019
Q2
$0 Hold
2
﹤0.01% 4087
2019
Q1
$0 Hold
2
﹤0.01% 4088
2018
Q4
$0 Hold
2
﹤0.01% 4122
2018
Q3
$0 Hold
2
﹤0.01% 4188
2018
Q2
$0 Buy
+2
New +$327 ﹤0.01% 4216
2015
Q4
Sell
-1
Closed 4526
2015
Q3
$0 Buy
+1
New +$816 ﹤0.01% 4663

Other funds holding MCRB

PNC Financial Services Group's MCRB Position: Q1 2025 in Review

PNC Financial Services Group sold out of Seres Therapeutics (MCRB) in Q1 2025, closing a stake of 32 shares — an estimated $529 sold.

PNC Financial Services Group first reported a position in MCRB in Q3 2015 and held it in 14 quarters. The position peaked at $4.28K in Q3 2023. 63 funds tracked by Wall St. Rank hold MCRB as of Q1 2025.

  • PNC Financial Services Group reported no remaining Seres Therapeutics position as of Q1 2025 after selling out during the quarter.
  • PNC Financial Services Group sold 32 Seres Therapeutics shares in Q1 2025, an estimated $529.
  • PNC Financial Services Group first reported a position in Seres Therapeutics in Q3 2015 and held it in 14 quarters.
  • PNC Financial Services Group's Seres Therapeutics position peaked at $4.28K in Q3 2023.
  • 63 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2025.

Based on PNC Financial Services Group's 13F filing for Q1 2025, filed 9 May 2025.